229 related articles for article (PubMed ID: 30249391)
1. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.
Pelosi G; Papotti M; Righi L; Rossi G; Ferrero S; Bosari S; Calabrese F; Kern I; Maisonneuve P; Sonzogni A; Albini A; Harari S; Barbieri F; Capelletto E; Catino AM; Cavone D; De Palma A; Fusco N; Lunardi F; Maiorano E; Marzullo A; Novello S; Papanikolaou N; Pasello G; Pennella A; Pezzuto F; Punzi A; Prisciandaro E; Rea F; Rosso L; Scattone A; Serio G
J Thorac Oncol; 2018 Nov; 13(11):1750-1761. PubMed ID: 30249391
[TBL] [Abstract][Full Text] [Related]
2. Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases.
Zhang YZ; Brambilla C; Molyneaux PL; Rice A; Robertus JL; Jordan S; Lim E; Lang-Lazdunski L; Begum S; Dusmet M; Anikin V; Beddow E; Finch J; Asadi N; Popat S; Cookson WOC; Moffatt MF; Nicholson AG
Am J Surg Pathol; 2020 Mar; 44(3):347-356. PubMed ID: 32045387
[TBL] [Abstract][Full Text] [Related]
3. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
4. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
5. c-Met expression and MET amplification in malignant pleural mesothelioma.
Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
7. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
8. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
9. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
[TBL] [Abstract][Full Text] [Related]
11. Reproducibility of histological subtyping of malignant pleural mesothelioma.
Brčić L; Jakopović M; Brčić I; Klarić V; Milošević M; Sepac A; Samaržija M; Seiwerth S
Virchows Arch; 2014 Dec; 465(6):679-85. PubMed ID: 25300229
[TBL] [Abstract][Full Text] [Related]
12. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
13. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
Vigneswaran WT; Kircheva DY; Ananthanarayanan V; Watson S; Arif Q; Celauro AD; Kindler HL; Husain AN
Ann Thorac Surg; 2017 Mar; 103(3):962-966. PubMed ID: 27765170
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of pleural biopsy for the diagnosis of histologic subtype of malignant pleural mesothelioma: Necropsy-based study of 134 cases.
Barbieri PG; Consonni D; Schneider M
Tumori; 2022 Feb; 108(1):26-32. PubMed ID: 33719756
[TBL] [Abstract][Full Text] [Related]
15. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
Meyerhoff RR; Yang CF; Speicher PJ; Gulack BC; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
J Surg Res; 2015 Jun; 196(1):23-32. PubMed ID: 25791825
[TBL] [Abstract][Full Text] [Related]
16. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.
Rosen LE; Karrison T; Ananthanarayanan V; Gallan AJ; Adusumilli PS; Alchami FS; Attanoos R; Brcic L; Butnor KJ; Galateau-Sallé F; Hiroshima K; Kadota K; Klampatsa A; Stang NL; Lindenmann J; Litzky LA; Marchevsky A; Medeiros F; Montero MA; Moore DA; Nabeshima K; Pavlisko EN; Roggli VL; Sauter JL; Sharma A; Sheaff M; Travis WD; Vigneswaran WT; Vrugt B; Walts AE; Tjota MY; Krausz T; Husain AN
Mod Pathol; 2018 Apr; 31(4):598-606. PubMed ID: 29327706
[TBL] [Abstract][Full Text] [Related]
17. A Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma With a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS).
Fuchs TL; Chou A; Aksoy Y; Mahjoub M; Sheen A; Sioson L; Ahadi M; Gill AJ
Am J Surg Pathol; 2022 Jun; 46(6):774-785. PubMed ID: 34907994
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).
Yoneda K; Tanaka F; Kondo N; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Tabata C; Nakano T; Hasegawa S
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S472-80. PubMed ID: 24306661
[TBL] [Abstract][Full Text] [Related]
19. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
20. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]